- Probiotics or synbiotics were linked to improved cognitive performance (SMD 0.50; 95% CI 0.19 to 0.81; P=0.002) amid high heterogeneity.
- Overall evidence certainty was very low due to risk of bias, substantial heterogeneity, and imprecision; cautious interpretation required.
- Exploratory subgroup analyses found no significant effect modifiers by disease, duration, intervention type, age, strain, dosage, or cognitive instrument.
Ageing Res Rev. 2026 Nov 9:103442. doi: 10.1016/j.arr.2026.103442. Online ahead of print.
ABSTRACT
OBJECTIVE: To systematically evaluate the effects of probiotics or synbiotics on cognitive function in individuals with mild cognitive impairment, Alzheimer’s disease, and related cognitive decline.
METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 20 September 2026. Randomized controlled trials comparing viable probiotics or synbiotics with placebo or usual care were included. Cognitive changes were pooled as standardized mean differences (SMDs) using a random-effects model. Subgroup, sensitivity, RoB 2, Egger, and GRADE assessments were conducted.
RESULTS: Ten trials involving 739 participants were included. Probiotics or synbiotics were associated with a possible improvement in cognitive function (SMD = 0.50, 95% CI: 0.19, 0.81; P = 0.002; Ι2 = 76%). The approximate 95% prediction interval was -0.57 to 1.57. No statistically significant differences in treatment effects were detected between subgroups defined by disease category, intervention duration, intervention type, study-level mean age, strain composition, dosage, or cognitive instrument. The effect was numerically larger in studies with a mean age ≤ 70 years, but this difference was not significant (P = 0.17) and was sensitive to individual studies. Sensitivity analyses maintained the direction and statistical significance of the pooled effect. Egger’s test showed no significant small-study effects (Z = 1.00, P = 0.318). The certainty of evidence was very low.
CONCLUSION: Probiotics or synbiotics may improve cognitive test performance, but the certainty of evidence is very low because of risk of bias, substantial heterogeneity, and imprecision. Exploratory subgroup analyses did not provide clear evidence that disease category, intervention duration, intervention type, study-level mean age, strain composition, dosage, or cognitive assessment instrument modified the treatment effect. Larger, well-designed randomized trials are needed.
PMID:43003143 | DOI:10.1016/j.arr.2026.103442
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

